### Edgar Filing: INTERCEPT PHARMACEUTICALS INC - Form 4

#### INTERCEPT PHARMACEUTICALS INC

Form 4

September 23, 2015

September 25, 201	13					
FORM 4				OMB AP	PROVAL	
	UNITED STATES	SECURITIES AND EXCHANGE C Washington, D.C. 20549	COMMISSION	OMB Number:	3235-0287	
Check this box if no longer	CT A TEMENIT O	Expires:	January 31, 2005			
subject to Section 16. Form 4 or	Section 16. SECURITIES					
Form 5	Filed pursuant to Section 17(a) of the 30(h)	response	0.5			
(Print or Type Respon	ses)					
1. Name and Address WILLIAMS NIC	of Reporting Person * OLE	2. Issuer Name <b>and</b> Ticker or Trading Symbol	5. Relationship of I Issuer	Reporting Person	on(s) to	
		INTERCEPT PHARMACEUTICALS INC [ICPT]	(Check	all applicable	)	

C/O INTERCEPT PHARMACEUTICALS, INC., 450 W. 15TH STREET, SUITE 505

(First)

(Middle)

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

(Month/Day/Year)

09/21/2015

3. Date of Earliest Transaction

6. Individual or Joint/Group Filing(Check

10% Owner

\_\_\_ Other (specify

Applicable Line)

\_X\_\_ Director

\_ Officer (give title

\_X\_ Form filed by One Reporting Person \_\_\_\_ Form filed by More than One Reporting

Person

NEW YORK, NY 10011

(Last)

(City)	(State)	(Zip) Tabl	e I - Non-I	Derivative	Secui	rities Acqu	ired, Disposed of	, or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securi on(A) or D (Instr. 3,	ispose 4 and (A) or	ed of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/21/2015		M(1)	973	A	\$ 9.8223	1,935	D	
Common Stock	09/21/2015		S <u>(1)</u>	973	D	\$ 194.82	962	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

## Edgar Filing: INTERCEPT PHARMACEUTICALS INC - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number on Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Pr Deri Secu (Inst
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Options to Purchase Common Stock	\$ 9.8223	09/21/2015		M <u>(1)</u>	973	(2)	09/16/2019	Common Stock	973	

# **Reporting Owners**

Reporting Owner Name / Address		Relationships					
	Director	10% Owner	Officer	Other			

WILLIAMS NICOLE C/O INTERCEPT PHARMACEUTICALS, INC. 450 W. 15TH STREET, SUITE 505 NEW YORK, NY 10011



# **Signatures**

/s/ Bryan Yoon, as attorney-in-fact 09/23/2015

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reported transaction was made pursuant to a 10(b)5-1 plan adopted by the reporting person on November 21, 2014.
- (2) All shares underlying this option have vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2